Liraglutide

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that shares 97% sequence homology with endogenous human GLP-1. It was developed by Novo Nordisk and approved by the FDA in 2010 (Victoza for T2D) and 2014 (Saxenda for obesity), making it one of the landmark medications in modern metabolic medicine and the immediate predecessor to the even more potent semaglutide.

The structural modification that defines liraglutide is the attachment of a C16 fatty acid side chain (palmitic acid) to the lysine residue at position 26 via a glutamic acid-mini PEG linker. This modification enables reversible albumin binding in the bloodstream, dramatically extending the half-life from the native GLP-1's 2-3 minutes to approximately 13 hours - enabling once-daily subcutaneous dosing.

Mechanistically, liraglutide acts on GLP-1 receptors (GLP-1R) throughout the body. In the pancreas, GLP-1R activation on beta cells stimulates glucose-dependent insulin secretion - a critical feature that means insulin release only increases when blood glucose is elevated, significantly reducing hypoglycemia risk compared to older diabetes medications. Simultaneously, glucagon secretion from alpha cells is suppressed, further improving glycemic control.

In the brain, liraglutide crosses the blood-brain barrier to activate GLP-1Rs in the hypothalamus and brainstem, particularly in areas regulating appetite and energy homeostasis. This central action reduces appetite, increases satiety signalling, and decreases caloric intake - the primary mechanism driving the weight loss effects of the Saxenda formulation.

The cardiovascular benefits demonstrated in the LEADER trial were landmark findings. In 9,340 high-risk cardiovascular patients followed for 3.8 years, liraglutide reduced the primary composite endpoint of major adverse cardiovascular events by 13%. Cardiovascular mortality specifically was reduced by 22%. The mechanisms appear to involve both metabolic improvements (glucose, weight, blood pressure) and direct vascular effects through endothelial GLP-1Rs.

Liraglutide has also demonstrated meaningful hepatic effects. The LEAN trial showed that liraglutide produced histological improvement in non-alcoholic steatohepatitis (NASH) in 39% of treated patients versus 9% in placebo, with resolution of NASH in some patients - establishing GLP-1 receptor agonists as potential therapeutic tools in liver disease.

The development of liraglutide established the proof of concept for GLP-1 receptor agonists as multipurpose metabolic agents. Its success directly led to the development of semaglutide, which improved on liraglutide's half-life (168 hours vs 13 hours), enabling weekly dosing and producing substantially greater weight loss (15-20% vs 5-9%). Understanding liraglutide's pharmacology is essential context for the entire GLP-1 receptor agonist class.